Prevention of the transmission of prion diseases in healthcare settings

Prions in Humans and Animals

Volumn , Issue , 2006, Pages 546-560

  Hörnlimann, Beat ^a   Pauli, Georg ^b   Lemmer, Karin ^b   Beekes, Michael ^b   Mielke, Martin ^b  

^a BSE71 92 SVISS Consulting   (Switzerland)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956180910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110200171     Document Type: Chapter

References (75)

1. Beekes M, Mielke M, Pauli G, et al. Aspects of risk assessment and risk management of nosocomial transmission of classical and variant Creutzfeldt-Jakob disease with special attention to German regulations. Contrib Microbiol 2004; 11:117-135.
2. WHO. Infection control guidelines for trans-missible spongiform encephalopathies. WHO/CDS/CSR/APH/2000.3. 1999. Webpage 2006: www.who.int/csr/resources/publications/bse/whocdscsraph2003.pdf.
3. Advisory Committee on Dangerous Pathogens & Spongiform Encephalopathy Advisory Com-mittee. Transmissible spongiform encephalo-pathy agents: safe working and the prevention of infection. 1998. Webpage 2006: www.archive.official-documents.co.uk/document/doh/spongifm/report.htm.
4. Department of Health (UK). Webpage 2006: www.dh.gov.uk/PublicationsAndStatistics/Pub-Hcations/PublicationsPolicyAndGuidance/Pub-HcationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4113541&chk=Aklzhj.
5. Medicines and Healthcare Products Regulatory Agency. Webpage 2006: www.mhra.gov.uk.
6. British dental association (BDA). Webpage 2006: www.bda-dentistry.org.uk.
7. Department of Health. UK committees. Webpage 2006: www.advisorybodies.doh.gov.uk.
8. Fondation recherche médicale. Maladie de Creutzfeldt-Jakob et maladies á prions. Webpage 2006: www.frm.org/informez.
9. Direction générale de la sante et Direction de Hospitalisation et de l'organisation de soins. Circulaire DGS/5 C/DHOS/E 2 n° 2001-138 du 14 mars 2001 relative aux précautions á observer lors de soins en vue de reduire les risques de transmission d'agents transmissibles non convention-nels. 2001. Webpage 2006: www.sante.gouv.fr/adm/dagpb/bo/2001/01-ll/a0110756.htm.
10. Comité technique national des infections nosocomials. Disinféction des dispositifs médicaux en anesthésie et en réanimation. Webpage 2006: www.sfar.org/pdf/desinfdm.pdf.
11. Swiss Public Health Office (BAG). Verordnung über die Prävention der Creutzfeldt-Jakob-Krankheit bei chirurgischen und medizinischen Eingriffen (CJK-Verordnung). Bull BAG 2006; Nr.3: 28-30. Webpage 2006: www.bag.admin.ch/prionen/01875/index.html.
12. Harbarth S, Alexiou A, Pittet D, et al. Creutz-feldt-Jakob Krankheit: Vorsichtsmassnahmen zur Prävention iatrogener Übertragungen im Spital. Swiss-NOSO 1996; 3(2):9-ll. Webpage 2006: www.chuv.ch/swiss-noso/d94al.htm.
13. Iffenecker A and Ruef C. Übertragungsrisiko von Prionen: Stellungnahme zur Aufbereitung thermostabiler chirurgischer Instrumente vor der Sterilisation. Swiss-NOSO 2002; 9(4):25-28. Webpage 2006: www.chuv.ch/swiss-noso/d32al.htm.
14. Simon D and Pauli G. Krankenversorgung und Instrumentensterilisation bei CJK-Patienten und CJK-Verdachtsfällen. Bundesgesundhbl 1998; 41:279-285.
15. Anonym. Die Variante der Creutzfeldt-Jakob-Krankheit (vCJK): Epidemiologic Erkennung. Diagnostik und Prävention unter besonderer Be-rficksichtigung der Risikominimierung einer iat-rogenen Übertragung durch Medizinprodukte. insbesondere chirurgische Instrumente. Ab-schlussbericht der Task Force vCJK zu diesem Thema. Bundesgesundheitsbl - Gesundheits-forsch - Gesundheitsschutz 2002; 45:376-394. Webpage 2006: www.rki.de/cln_006/nn_226786/DE/Content/Infekt/Krankenhaushygiene/Er-reger_ausgewaehlt/CJK/CJK_pdf_02,tem-plateId=raw)Property=publicationFile.pdf/CJK_pdf_02.
16. Anonymous. Creutzfeldt-Jakob disease and other human transmissible spongiform encepha-lopathies: guidelines on patient management and infection control. Working Party of the National Health Advisory Committee of the National Health and Medical Research Council. Canberra: Australian Government Publishing Service, 1996.
17. Anonymous. Creutzfeldt-Jakob disease and other human transmissible spongiform encepha-lopathies - guidelines on patient management and infection control. 1995. Webpage 2006: www.nhmrc.gov.au/publications/_files/with-drawn/ic5.pdf.
18. Steelman VM. Creutzfeld-Jakob disease: recom-mendations for infection control. Am J Infect Control 1994; 22:312-318.
19. CDC. Prion diseases. Webpage 2006: www.cdc.gov/ncidod/dvrd/prions.
20. Berger JR and David NJ. CJD in health care workers. Neurology 1993; 43:2421.
21. Berger JR and David NJ. Creutzfeldt-Jakob dis-ease in a physician: a review of the disorder in healthcareworkers.Neurologyl993;43:205-206.
22. Gorman DG, Benson DF, Vogel DG, et al. Creutzfeldt-Jakob disease in a pathologist. Neurology 1992; 42:463.
23. Mitrova E and Belay G. Creutzfeldt-Jakob dis-ease in health professionals in Slovakia. Eur J Epidemiol 2000; 16(4):353-355.
24. Sitwell L, Lach B, Attack E, et al. Creutzfeldt-Jakob disease in histopathology technicians. N Engl J Med 1988; 318:854.
25. Will RG, EsmondeTFG, Matthews WB. Creutz-feldt-Jakob disease epidemiology. In: Prusiner SB, Collinge J, Powell J, et al., editors. Prion diseases of humans and animals. Ellis Horwood. New York, 1992:188-199.
26. Cooke J. Cannibals, cows and the CJD catas-trophe. Random House, Australia, 1998.
27. Schoene WC, Masters CL, Gibbs CJ Jr, et al. Transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease) - atypical clinical and pathological findings. Arch Neurol 1981; 38:473-477.
28. Miller DC. Creutzfeldt-Jakob disease in his-topathology technicians. N Engl J Med 1988: 318:853-854.
29. Brown P. Transmissible spongiform encepha-lopathy - Chapter 43. In: Goetz C, editor. Text-book of Clinical Neurology. W.B. Saunders. Philadelphia, PA, 2006.
30. Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person trans-mission of Creutzfeldt-Jakob disease by surgery (letter). Lancet 1977;1:478-479.
31. Croxson M, Brown P, Synek B, et al. A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand. Neurology 1988; 38:1128-1130.
32. Rappaport EB. Iatrogenic Creutzfeldt-Jakob disease. Neurology 1987; 37:1520-1522.
33. WHO. Consultation on medicinal and other products in relation to human and animal trans-missible spongiform encephalopathies. With the participation of the Office International des Epi-zooties (OIE) (report). Document WHO/EMC/ZOO/97 3-WHO/BLG/97 2, World Health Organization, 1997.
34. Sato T, Hoshi K, Yoshino H, et al. Creutzfeldt-Jakob disease associated with cadaveric dura ma-ter grafts - Japan, January 1979 to May 1996. MMWR 1997; 46:1066-1069.
35. Hilton DA, Ghani AC, Conyers L, et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. BMJ 2002; 325(7365): 633-634.
36. Ghani AC, Ferguson NM, Donnelly CA, et al. Predicted vCJD mortality in Great Britain. Nature 2000; 406(6796):583-584.
37. Department of Health. Assessing the risk of vCJD transmission via surgery: an interim re-view. 2005. Webpage 2006: www.dh.gov.uk.
38. Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 348(8):711-719.
39. Reuber M, Al-Din AS, Baborie A, et al. New variant Creutzfeldt-Jakob disease presenting with loss of taste and smell. J Neurol Neurosurg Psychiatr2001;71(3):412-413.
40. Pauli G. Tissue safety in view of CJD and variant CJD (review). Cell Tissue Bank 2005; 6:191-200.
41. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004: 363(9407):417-421.
42. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004: 364(9433):527-529.
43. Health Protection Agency (UK). New case of variant CJD associated with blood transfusion (press release). Webpage 2006: www.hpa.org.uk/hpa/news/articles/press_Releases/2006/060209_cjd.htm.
44. Glatzel M, Abela E, Maissen M, et al. Extradural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003: 349(19):1812-1820.
45. Peden AH, Ritchie DL, Head MW, et al. Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease. Am J Pathol. 2006; 168(3):927-35.
46. Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358(9277):171-180.
47. Hill AF, Zeidler M, Ironside J, et al. Diagnosis of new variant Creutzfeldt-Jakob disease by ton-sil biopsy. Lancet 1997; 349:99-100.
48. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353(9148): 183-189.
49. Ironside JW Pathology of variant Creutzfeldt-Jakob disease. Arch Virol Suppl 2000;(16):143-151.
50. Hilton DA, Fathers E, Edwards P, et al. Prion immunoreactivity in appendix before clinical on-set of variant Creutzfeldt-Jakob disease. Lancet 1998; 352(9129):703-704.
51. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumu-lation in UK tissue samples. J Pathol 2004; Epub 21 May 2004. DOI 10.1002/path.l580.
52. Mabbott NA and Bruce ME. The immunobiology of TSE diseases. J Gen Virol 2001; 82(Pt 10):2307-2318.
53. Klein MA, Frigg R, Flechsig E, et al. A crucial role for B-cells in neuroinvasive scrapie. Nature 1997; 390:687-690.
54. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform en-cephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39(11-12):1169-1178.
55. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38(9):810-816.
56. Bruce ME, McConnell I, Will RG, et al. Detection of variant Creutzfeldt-Jakob disease infec-tivity in extraneural tissues. Lancet 2001: 358(9277):208-209.
57. Anonym. Bericht der Arbeitsgruppe "Gesamt-strategie Blutversorgung angesichts vCJK". 2001. Webpage 2006: www.pei.de/SharedDocs/Downloads/blut/gesamtstrategie-bericht,templateId=raw,property=publicationFile.pdf/gesamtstrategie-bericht.pdf. [Update published on 13 April 2006; see Internet]
58. Flechsig E, Hegyi I, Enari M, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med 2001; 7(10):679-684.
59. Spencer RC and Ridgway GL. Sterilization issues in vCJD - towards a consensus: meeting between the Central Sterilizing Club and Hospital Infection Society. 12th September 2000. J Hosp Infect 2002; 51(3):168-174.
60. Department of Health. CJD publications. Web-page 2006: www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CJD/fs/en
61. Anonymous. Creutzfeldt-Jakob lending devices program of the University of Göttingen. Endo-Praxis 2001; 2:38.
62. Lemmer K, Mielke M, Pauli G, et al. Decontamination of surgical instruments from prion pro-teins: in vitro studies on the detachment, de-stabilization and degradation of PrPSc bound to steel surfaces. J Gen Virol 2004; 85(12):3805-3816.
63. Baier M, Schwarz A, Mielke M. Activity of an alkaline 'cleaner' in the inactivation of the scrapie agent. J Hosp Infect 2004; 57(l):80-84.
64. Head MW, Ritchie D, Smith N, et al. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an im-munohistochemical, quantitative, and biochemical study. Am J Pathol 2004; 164(1):143-153.
65. Department of Health, Economics and Oper-ational Division. Risk assessment for trans-mission of vCJD via surgical instruments: a modelling approach and numerical scenarios. Government Operational Research Service. London, 2001.
66. Anonym. Empfehlungen der Kommission für Krankenhaushygiene und Infektionsprävention - Anforderungen an die Hygiene bei der Auf-bereitung von Medizinprodukten. Bundesge-sundheitsbl - Gesundheitsforsch - Gesundheits-schutz 2001; 44:1115-1126.
67. Kampf G, Bloss R, Martiny H. Surface fixation of dried blood by glutaraldehyde and peracetic acid. J Hosp Infect 2004; 57(2):139-143.
68. Lim R, Dhillon B, Kurian KM, et al. Retention of corneal epithelial cells following Goldmann tonometry: implications for CJD risk. Br J Oph-thalmol 2003; 87(5):583-586.
69. Mehta JS, Osborne RJ, Bloom PA. Variant CJD and tonometry. Br J Ophthalmol 2004; 88(4): 597-598.
70. Macalister GO and Buckley RJ. The risk of transmission of variant Creutzfeldt-Jakob disease via contact lenses and ophthalmic devices. Cont Lens Anterior Eye 2002; 25(3):104-136.
71. Smith A and Bagg J. CJD and the dentist. Dent Update 2003; 30(4):180-186.
72. Smith A. CJD and the dentist. Dent Update 2003; 30(8):462-463.
73. Department of Health. Risk assessment for vCJD and dentistry 2003. Webpage 2006: www.dh.gov.uk/PublicationsAndStatistics/Pub-Hcations/PublicationsPolicyAndGuidance/Pub-licationsPolicyAndGuidanceArticle/fs/en?CON-TENTJD=4084662&chk=twiXsY
74. Whitley RJ, MacDonald N, Asher DM. American Academy of Pediatrics. Technical report: transmissible spongiform encephalopathies: a re-view for pediatricians. Committee on Infectious Diseases. Pediatrics 2000; 106(5):1160-1165.
75. HSAC guidance on "Safe disposal on clinical waste" 1999; HSE Books ISBNO-7176-24492-7. Webpage 2006: www.advisorybodies.doh.gov.uk/acdp/tseguidance/tseguidancepart4.pdf